Compare AVXL & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVXL | DBI |
|---|---|---|
| Founded | 2004 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.2M | 315.8M |
| IPO Year | 2013 | 2005 |
| Metric | AVXL | DBI |
|---|---|---|
| Price | $2.73 | $6.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $22.00 | $6.75 |
| AVG Volume (30 Days) | ★ 1.3M | 778.5K |
| Earning Date | 05-08-2026 | 06-09-2026 |
| Dividend Yield | N/A | ★ 2.73% |
| EPS Growth | N/A | ★ 15.00 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $2,892,671,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | N/A | $1.88 |
| P/E Ratio | ★ N/A | $317.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.41 | $2.37 |
| 52 Week High | $13.99 | $9.17 |
| Indicator | AVXL | DBI |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 40.05 |
| Support Level | $2.62 | $6.13 |
| Resistance Level | $3.07 | $8.15 |
| Average True Range (ATR) | 0.18 | 0.63 |
| MACD | 0.02 | -0.22 |
| Stochastic Oscillator | 48.48 | 4.04 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in two reportable segments: the Retail segment and the Brand Portfolio segment. The Retail segment, which derives key revenue, operates the DSW Designer Shoe Warehouse ("DSW") banner through its direct-to-consumer stores and e-commerce sites in the United States ("U.S.") and Canada, and the Shoe Co. and Rubino banners through its direct-to-consumer stores and e-commerce sites in Canada. The Brand Portfolio segment principally earns revenue from the wholesale of its exclusive and licensed brands to retailers, its Retail segment, and international distributors, and the sale of its Vince Camuto, Keds, and Topo brands through direct-to-consumer e-commerce sites.